Auransa
Auransa is a clinical-stage, AI-native biopharma company that leverages a proprietary AI platform to harness available human disease data for discovering novel therapeutics, particularly in cancer care. Their mission is to raise the standard of cancer treatment by developing smarter, more effective therapies through innovative data science and AI technologies. They focus on advancing treatments for cancers and cancer-related diseases, including liver cancer, prostate cancer, breast cancer, and head and neck cancers, with a goal of improving patient outcomes and clinical success rates.
Industries
Nr. of Employees
small (1-50)
Patents
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-11786503-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-11166936-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-10874633-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-10806716-B2
View Details
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-11786503-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-11166936-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-10874633-B2
View DetailsPharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US-10806716-B2
View DetailsProducts
Oral small-molecule candidate for liver cancer (Phase 1 clinical candidate)
A novel orally active small-molecule clinical candidate developed from AI-driven discovery and preclinical validation; being evaluated in a Phase 1 dose-escalation study for advanced primary liver cancers and liver‑predominant metastatic disease to assess safety, tolerability, and pharmacokinetics.
Cardioprotective small-molecule candidate for reducing chemotherapy cardiotoxicity (IND-enabling)
Preclinical/IND-enabling compound discovered via computational analysis aimed at reducing anthracycline-induced cardiotoxicity to improve chemotherapy tolerability.
Oral small-molecule candidate for liver cancer (Phase 1 clinical candidate)
A novel orally active small-molecule clinical candidate developed from AI-driven discovery and preclinical validation; being evaluated in a Phase 1 dose-escalation study for advanced primary liver cancers and liver‑predominant metastatic disease to assess safety, tolerability, and pharmacokinetics.
Cardioprotective small-molecule candidate for reducing chemotherapy cardiotoxicity (IND-enabling)
Preclinical/IND-enabling compound discovered via computational analysis aimed at reducing anthracycline-induced cardiotoxicity to improve chemotherapy tolerability.
Services
Joint research collaborations to apply AI/ML on public and partner datasets to discover and prioritize therapeutic candidates.
Partnerships to advance IND-enabling studies and early-phase clinical trials, including site collaborations for Phase 1 execution.
Joint research collaborations to apply AI/ML on public and partner datasets to discover and prioritize therapeutic candidates.
Partnerships to advance IND-enabling studies and early-phase clinical trials, including site collaborations for Phase 1 execution.
Expertise Areas
- AI-driven drug discovery
- Biomarker-driven patient stratification
- Preclinical pharmacology and toxicology
- Early-phase clinical trial management
Key Technologies
- Multi-omics data integration
- AI / machine learning for target and compound discovery
- Gene expression profiling and analysis
- Patient subtyping algorithms